Phio Pharmaceuticals: decline stalls, ADX keeps sliding
Phio Pharmaceuticals stock rises 1.5% as sellers stay in control
Phio Pharmaceuticals: decline stalls, ADX keeps sliding
Our view last week
Money flow on Phio Pharmaceuticals stock stays firmly on the buy side for a third straight week, yet the ADX keeps sliding: the decline keeps losing conviction. The week closed down 1.4% despite 62% of trading on the buy side, a divergence that reads more like hesitation than strength. Price remains boxed between support in the 0.95 area and resistance in the 1.03 area, with the short over 13% in profit. Worth watching closely: earnings land this week.
This week's summary
Phio Pharmaceuticals' Sell signal has been under management for 15 weeks, with the short over 12% in the money. This week the price rose 1.5% even though 64% of trading sat on the sell side; last week ran the opposite way, buyers in control yet the price still fell, the same hesitation, flipped. The stock stays boxed between support in the 1.03 area and resistance in the 1.06 area, with the ADX still sliding.
IQS Phase
52
ordinary
Signal Strength
2
decline losing steam
Sizing
MINIMUM
Ranking
#96 / 122
US stocks
Trade P&L %
+12.61%
from signal to date, no stop loss
Rank position
ranks 96th among the 122 sell signals for US stocks in our ranking, with a signal strength of 2 out of 100.
Sector context
SectorHealth Care
Benchmark ETFXLV
Sector regimein strong phase
Performanceweekly +1.93% · monthly +2.08%
PHIO belongs to the health care sector (reference ETF XLV). The sector is classified in strong phase according to our weekly reading.
restricted Platinum content